Innovating Works

DYMSA INGENIERIA

Activa
MAP-AD: A Methylation Profiling Diagnostic for Early Diagnosis of Alzheimer s disease ADMIT THERAPEUTICS tramitó un H2020: H2020-EIC-SMEInst-2018-2020 Each year an estimated 40M people suffer from Alzheimer’s disease (AD) globally, and a new case is diagnosed every 4 seconds, leading to a s...
2020-08-24 - 2024-03-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.